The company recently presented its first assay performance data in a multi-cancer setting, showing high accuracy, even in the most challenging tumor types.
Physicians are beginning to face patient questions about commercially available tests without definitive utility data to guide them.
At AACR, the company highlighted new prospective and retrospective data that it believes helps set its platform apart from other available ctDNA technologies.
The firm is seeing the fruit of a two-year investment in transitioning from a research lab to a clinical focus.
Behavioral Nudges in Study Increase Germline Genetic Testing Referrals but Not Patient Uptake
At AACR, a study explored the impact of a chain of default notifications in prompting physician referrals and patient adoption of genetic testing in colorectal cancer patients.